Blood-Brain Barrier Market Size worth close to USD 2.90 billion by 2035 | Roots Analysis

Over time, extensive R&D efforts have resulted in the development of a number of versatile blood-brain barrier technologies. These technologies have been designed either to externally alter the permeability of the blood-brain barrier or augment the blood-brain barrier penetrating capabilities of compatible pharmacological interventions.

Owing to these advancements, there has been a marked rise in the number of new entrants in this field and we anticipate significant growth in the coming years.  Currently, blood-brain barrier market is driven by technology licensing activity, with drug developers collaborating with platform providers to grow their respective therapeutic pipelines.

Key Report Takeaways

§  Presently, more than 125 blood brain barrier penetrating therapies are developed / currently being evaluated in different stages of development across the world; majority of the blood brain barrier therapy developers are based in North America

§  Players have signed several strategic partnerships, raised funding, expanded current facilities and launched new therapies, to enhance their capabilities

§  Since 2019, nearly 1,295 patents related to blood-brain barrier have been filed / granted by various stakeholders to protect the intellectual property generated within this domain

§  Around 17% of the blood-brain barrier therapies are currently in the later phases of development (Phase II and III); majority of these are being administered through intravenous route

§  Close to 45 players are engaged in offering blood-brain barrier technologies; majority of these players are based in Europe, followed by North America

§  As a result of the growing demand for blood-brain barrier therapies, the blood-brain barrier market is likely to grow at a CAGR of ~49% over the next 12 years

Competitive Landscape:

The blood-brain barrier market features more than 31 unique blood brain barrier penetration technologies, which are being investigated by various companies and academic research institutes. Close to 70% technologies have been commercialized and are being utilized to design drugs that can penetrate the blood brain barrier. Further, around 45% blood brain barrier penetration technologies are based on biological approach to enable the passage of drugs through the elusive BBB. In terms of blood brain barrier penetration technology developers, the overall landscape seems to be well-fragmented, comprising of very large, large, mid-sized, small and very small blood brain barrier penetration technology developers. Over 45% of the blood brain barrier penetration technology developers are based in North America and Europe.

The current market landscape features the presence of over 125 blood-brain barrier penetrating therapies that are either approved or are currently being evaluated in different stages of development. Close to 40% of blood-brain barrier penetrating therapies are in preclinical stage. Further, the majority (60%) of the BBB penetrating therapies are biologics as biologics have demonstrated great potential in the treatment the brain diseases.

Regional Outlook

Based on the key geographical regions, the blood-brain barrier market can be segmented into three major regions, including North America, Europe, and Asia Pacific and Rest of the World. Notably, Asia Pacific and Rest of the World is anticipated to dominate the market in 2024 and this trend is likely to change during the forecast period.

Due to various factors such as the presence of several well-established drug developers with extensive manufacturing capabilities in North America. Additionally, the advanced healthcare infrastructure and research capabilities in North America enable drug developers to conduct extensive clinical trials required to meet the stringent regulatory guidelines of the drug approval bodies. North America is likely to capture the largest share of blood-brain barrier market during the forecast period.

Market Key Players

Examples of key companies engaged in blood-brain barrier market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Aldevron, ICBI, Denali Therapeutics, JCR Pharmaceuticals, Cyclenium Pharma, Lauren Sciences, biOasis Technologies, Ossianix, Angiochem, Genervon Biopharmaceuticals, NEUWAY Pharma, Tranquis Therapeutics, CERES BRAIN Therapeutics, Nanomerics, Reglagene.

It is interesting to note that in January 2024, Vect-Horus entered into a partnership with Ionis Pharmaceuticals which aims to improve the systemic administration of RNA-targeted drugs for various neurological disorders. In this collaboration, Ionis Pharmaceuticals received exclusive licensing rights for a specified number of targets employing Vect-Horus' VECTrans technology.

This innovative platform enables the systemic delivery of RNA-targeted therapeutics, enabling them to cross the blood-brain barrier and target specific sites within the central nervous system. Such types of agreements are expected to drive the demand for blood-brain barrier penetrating therapies and technologies across the globe, resulting in substantial market growth during the forecast period.

Blood-Brain Barrier Market Segments

Based on the research, Roots Analysis has segmented the market by Type of Molecule, Target Indication, Route of Administration, Therapeutic Area and Key Geographical Regions.

Market Segments

by Type of Molecule

§  Small Molecule

§  Biologics

by Target Indication

§  Multiple Sclerosis

§  Amyotrophic Lateral Sclerosis

§  Mucopolysaccharidosis Type II (Hunter Syndrome)

§  Leptomeningeal Carcinomatosis

§  Mucopolysaccharidosis Type III A (Sanfilippo Syndrome A)

by Route of Administration

§  Oral

§  Intravenous

by Therapeutic Area

§  Neurodegenerative Disorders

§  Lysosomal Storage Disorders

§  Neuro-Oncology Disorders

by Key Geographical Regions

§  North America

§  Europe

§  Asia-Pacific

§  Rest of the World

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact US

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Email: sales@rootsanalysis.com